Clinical trials continue to be a driving force in ophthalmology, propelling the development of innovative treatments and technologies that improve patient outcomes. Editor’s Note: This is part three ...
Major MPS investor Caltagirone says there is no clash with CEO Lovaglio Gruppo Caltagirone, a major investor in Monte dei Paschi di Siena, said on Friday speculation about a clash with the Italian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback